Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients:

摘要: Background: Pancreatic adenocarcinoma has a poor prognosis, resulting in <10% survival rate at 5 years. Modulated electro-hyperthermia (mEHT) been increasingly used for pancreatic cancer palliative care and therapy. Objective: To monitor the efficacy safety of mEHT treatment advanced cancer. Methods: We collected data retrospectively on 106 patients affected by stage III-IV adenocarcinoma. They were divided into 2 groups: who did not receive (no-mEHT) treated with mEHT. performed applying power 60 to 150 W 40 90 minutes. The was associated chemotherapy and/or radiotherapy 33 (84.6%) patients, whereas 6 (15.4%) received alone. no-mEHT group 55.2% cases. Results: Median age sample 65.3 years (range = 31-80 years). After 3 months therapy, had partial response 22/34 (64.7%), stable disease 10/34 (29.4%), progressive 2/34 (8.3%). 3/36 (8.3%), 10/36 (27.8%), 23/36 (34.3%). median overall 18.0 1.5-68.0 months) 10.9 0.4-55.4 non-mEHT group. Conclusions: may improve tumor patients.